C-SD0WCleara
peptide therapeutics, impaired-p53 targeting, apoptosis
clearingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-SD0W
C-SD0WC-SD0Wpeptide therapeutics, impaired-p53 targeting, apoptosis
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cleara Biotech states that senescent cells accumulate in the body with age, are a major cause of health problems, and enable cancer development. The company says it discovered how these cells escape natural elimination and believes that targeting this failure can produce therapeutics that remove senescent cells, improve healthspan in old age, and counteract therapy resistance in late-stage cancer.
SourceCleara Biotech states that cellular senescence is a key driver of age-related health problems and cancer development, and that senescent cells persist because they escape the body’s natural elimination process. The company presents its discovery as identifying FOXO4 as a central survival mechanism in senescent cells, with FOXO4-p53 signaling helping these cells resist stress and avoid clearance. Based on that belief, Cleara argues that blocking this pathway can selectively induce apoptosis in senescent cells, improving healthspan in old age and helping counter therapy resistance in late-stage cancer.
SourceCleara Biotech states that senescent cells accumulate with age, are a major cause of health problems, and enable cancer development. The company says its researchers discovered how these cells escape natural elimination and that this mechanism centers on FOXO4-p53 signaling, making FOXO4 a key survival pivot in senescent cells. Based on that belief, Cleara is developing potent and selective FOXO4-p53 inhibitors to clear senescent cells and to address certain therapy-resistant cancers.
SourceCleara Biotech states that senescent cells accumulate in the body with age, are a major cause of health problems, and enable cancer development. The company says its researchers discovered how these cells escape natural elimination and that failure to clear them is a disease-causing mechanism. Based on this belief, Cleara is developing therapeutics intended to selectively eliminate senescent cells by targeting the FOXO4-p53 survival pathway.
Source